TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05603299

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Materials on the Dawn test
Description: Receive educational materials and sample test results replicating what physicians would receive in the real-world market as they learn about the probability of IO therapy response from the Dawn™ test.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Materials on the Dawn test
Description: Receive educational materials and sample test results replicating what physicians would receive in the real-world market as they learn about the probability of IO therapy response from the Dawn™ test.
Study: NCT06334770

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Roxolid implants
Description: four Straumann BLX® roxolid implant 15% zirconium and 85% titanium), 3.7 mm in diameter, and 10 mm in length.implants were selected with the following criteria: tapered, self-tapping, aggressively threaded,were inserted with novalock attachments.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Titanium implants
Description: four conventional acid etched pure implants tapered, self-tapping, threaded, two-piece, with the 10 mm length and 3.7 mm diameter were inserted with Sphero flex attachments.
Study: NCT06478927

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib capsules
Description: Palbociclib capsules, oral, 125 mg/dose, qd, take 3 weeks and then stop for 1 week, 28d for one treatment cycle until disease progression or intolerable toxicity.
Study: NCT06007573

Intervention type: DRUG
Group type: OTHER
Intervention: The control group received oral nimodipine tablets
Description: The control group received oral nimodipine tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: The control group received oral nimodipine tablets
Description: The control group received oral nimodipine tablets
Study: NCT04904601

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Kale supplement
Description: Kale (blanched freeze-dried Kale) group1

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Peas supplement
Description: placebo (Blanched Freeze-dried Peas) group2
Study: NCT04974359

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AG06466
Description: Lu AG06466 - capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo - capsules
Study: NCT00013182

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: social activity
Study: NCT06317766

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 2910 nm Fiber Laser Treatment; Pre-Clinical Histology Evaluation
Description: Treatment with 2910 nm fiber laser focusing on its diverse energy settings and histological evaluation post abdominoplasty.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 2910 nm Fiber Laser Treatment; Part 2 Histology Evaluation
Description: Healing Progression: Treatment with 2910 nm fiber laser focusing on its diverse energy settings and histological evaluation post abdominoplasty.
Study: NCT06247293

Intervention type: PROCEDURE
Intervention: intraperitoneal hyperthermic perfusion chemotherapy
Description: （1）Partial hepatectomy: The reasonable resection method was selected according to the tumor location, residual liver volume and the operation process. The tumor margin should be more than 1 cm, the abdominal cavity was flushed with sterile warm distilled water. In the control group,1-2 abdominal drainage tubes were placed on the hepatic cross-section, in the exposed group,4 abdominal perfusion tubes were placed in the right hepatic apex, splenic fossa, left and right pelvic cavity to perform HIPEC postoperatively.~(2) HIPEC: Temperature setting:43 °C perfusion time:60 min, perfusion speed:400-600 mL/min ,perfusion volume:3000 mL.~（3）Hepatic artery embolization：Through the common femoral artery, the catheter passed through the abdominal aorta, celiac trunk, the common hepatic artery and the inherent hepatic artery to the blood supply target artery of liver cancer. The embolic agent Lipiodol was mixed and injected to embolize the bleeding artery to stop bleeding.
Study: NCT05402267

Intervention type: PROCEDURE
Intervention: Adenoidectomy
Description: Adenoidectomy will be conducted in OA and CA groups

Intervention type: PROCEDURE
Intervention: Adenoidectomy
Description: Adenoidectomy will be conducted in OA and CA groups
Study: NCT06497439

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Silfamin
Description: 2 tablets of Silfamin 150 mg twice daily
Study: NCT06247293

Intervention type: PROCEDURE
Intervention: intraperitoneal hyperthermic perfusion chemotherapy
Description: （1）Partial hepatectomy: The reasonable resection method was selected according to the tumor location, residual liver volume and the operation process. The tumor margin should be more than 1 cm, the abdominal cavity was flushed with sterile warm distilled water. In the control group,1-2 abdominal drainage tubes were placed on the hepatic cross-section, in the exposed group,4 abdominal perfusion tubes were placed in the right hepatic apex, splenic fossa, left and right pelvic cavity to perform HIPEC postoperatively.~(2) HIPEC: Temperature setting:43 °C perfusion time:60 min, perfusion speed:400-600 mL/min ,perfusion volume:3000 mL.~（3）Hepatic artery embolization：Through the common femoral artery, the catheter passed through the abdominal aorta, celiac trunk, the common hepatic artery and the inherent hepatic artery to the blood supply target artery of liver cancer. The embolic agent Lipiodol was mixed and injected to embolize the bleeding artery to stop bleeding.

Intervention type: PROCEDURE
Intervention: intraperitoneal hyperthermic perfusion chemotherapy
Description: （1）Partial hepatectomy: The reasonable resection method was selected according to the tumor location, residual liver volume and the operation process. The tumor margin should be more than 1 cm, the abdominal cavity was flushed with sterile warm distilled water. In the control group,1-2 abdominal drainage tubes were placed on the hepatic cross-section, in the exposed group,4 abdominal perfusion tubes were placed in the right hepatic apex, splenic fossa, left and right pelvic cavity to perform HIPEC postoperatively.~(2) HIPEC: Temperature setting:43 °C perfusion time:60 min, perfusion speed:400-600 mL/min ,perfusion volume:3000 mL.~（3）Hepatic artery embolization：Through the common femoral artery, the catheter passed through the abdominal aorta, celiac trunk, the common hepatic artery and the inherent hepatic artery to the blood supply target artery of liver cancer. The embolic agent Lipiodol was mixed and injected to embolize the bleeding artery to stop bleeding.
Study: NCT05130866

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REC-2282
Description: Participants will receive REC-2282 3 times per week orally for 3 weeks followed by 1 week off for a 4-week cycle.
Study: NCT06646783

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [68Ga]Ga-NODAGA-SNA014
Description: Perform whole-body PET/CT scans on the subjects at 30 minutes (± 5 minutes), 60 minutes (± 10 minutes), 120 minutes (± 20 minutes), and 240 minutes (± 30 minutes) after administration. Among them, PET scanning can be performed on 1-2 subjects in a certain dose group or each dose group for 30-60 minutes. Among the four CT scans, one CT scan is a conventional low-dose CT scan (120mA), and the remaining three are extremely low-dose CT scans (10-20mA). The main researchers and nuclear medicine physicians can decide whether to change the subsequent image acquisition time and duration of the subjects based on the image information obtained from the enrolled subjects.
Study: NCT06646107

Intervention type: DEVICE
Intervention: MInimed 780G
Description: Minimed 780G HCL system (Metronic, Northridge, Ca, USA) is ConformitèEuropëenne(CE)-marked and includes additional functionality aiming to provide further protections from high glucose levels. When the system is used in Auto Mode automatically calculate the insulin dose based on information received from CGM. Signals are converted by the transmitter to sensor glucose values. Sensor values are then transmitted to the insulin pump. Sensor glucose and insulin delivery data are stored by the pump and may be uploaded. The HCL system can be programmed to automatically calculate insulin doses (both basal insulin and correction boluses) based on information received from CGM780G and the adherence to MD.
Study: NCT06407193

Intervention type: OTHER
Intervention: MRI and scintigraphy
Description: Gastric emptying measured with MRI and scintigraphy

Intervention type: OTHER
Intervention: MRI and scintigraphy
Description: Gastric emptying measured with MRI and scintigraphy
Study: NCT06497439

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablet of Silfamin
Description: 2 tablets of Silfamin Placebo twice daily
Study: NCT05528081

Intervention type: OTHER
Intervention: Phone interview
Description: Participants will be interviewed by phone at 3, 12, 24 months after the baseline MRI scans.

Intervention type: OTHER
Intervention: Phone interview
Description: Participants will be interviewed by phone at 3, 12, 24 months after the baseline MRI scans.
Study: NCT04634201

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral probiotics (L. reuteri)
Description: administration of probiotic containing tablets twice daily after tooth brushing for 3 months

Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: Placebo
Description: administration of a placebo twice daily after tooth brushing for 3 months
Study: NCT06457542

Intervention type: OTHER
Group type: OTHER
Intervention: Active Release Technique
Description: Active Release Therapy, which involves instructing the patient to sit and then positioning their shoulder in 90-degree abduction. The therapist will provide assistance to the patient's arm and then examine the supraspinous fossa by applying pressure with a finger. The patient will be instructed to gradually bring the arm towards the body as the therapist manipulates the muscle plane. This procedure should be repeated for a duration of 10 minutes, 3 times per week, over a duration of four weeks.

Intervention type: OTHER
Group type: OTHER
Intervention: Soft Tissue Mobilization
Description: Soft Tissue Mobilization (STM) targeting the subscapularis muscle. The participants will be placed in a position where their upper arm bone (humerus) is raised at a 45° angle, with the elbow bent at a 90° angle. Additionally, the humerus will be rotated outward to a position that is normally around 20° to 25° of external rotation. The subscapularis muscle remained examined by touch in the armpit area to locate regions of limited mobility due to myofascial limitations, trigger points or tense bands. The identified limitations remained addressed with STM, which included applying prolonged manual pressure and slow deep stroke to the subscapularis myofascial. This treatment was performed for a period of 7 minutes, three times a week, over a period of four weeks.
Study: NCT05652751

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nerve growth factor
Description: The patient first received an intramuscular injection of NGF or saline into the gluteus maximus.The 20ug nerve growth factor (NO.S20060051, Jinlujie) will be obtained from Hiteck Biopharmaceutical Co., Ltd, Wuhan, China. mNGF will be dissolved in 1 ml sterile water for injection and then injected intramuscularly at gluteal muscle, once a day for 4 weeks. Dose modification is not allowed for mNGF.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nerve growth factor
Description: The patient first received an intramuscular injection of NGF or saline into the gluteus maximus.The 20ug nerve growth factor (NO.S20060051, Jinlujie) will be obtained from Hiteck Biopharmaceutical Co., Ltd, Wuhan, China. mNGF will be dissolved in 1 ml sterile water for injection and then injected intramuscularly at gluteal muscle, once a day for 4 weeks. Dose modification is not allowed for mNGF.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: physiological saline
Description: Other patients will receive 1ml volume of physiological saline (PS) injected into the gluteal muscle, once a day for 4 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: physiological saline
Description: Other patients will receive 1ml volume of physiological saline (PS) injected into the gluteal muscle, once a day for 4 weeks.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EA
Description: Patients take supine position. After skin disinfection with 75% ethanol routine disinfection, the stainless needle (size 0.25mm×40mm, Hua Tuo brand, Suzhou Medical Supplies Company Ltd in Jiangsu, China) will be inserted in GV20（Baihui) and the stainless needle(size 0.25mm×25mm, described above) will be inserted in GV26 (Shuigou), acupoints will be stimulated manually until patients feel soreness, distension or heaviness (the reaction of De Qi). Then, the needles are stimulated by using an acupuncture point nerve stimulator (HANS-200, Nanjing Jinsheng, Ltd., China) with a frequency of 2/100 Hz and an intensity of 3 mA for 40 min (a homemade relay cycled power to the electrode for 6 sec on and 6 sec off), 28 days as a course of treatment, once a day.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EA
Description: Patients take supine position. After skin disinfection with 75% ethanol routine disinfection, the stainless needle (size 0.25mm×40mm, Hua Tuo brand, Suzhou Medical Supplies Company Ltd in Jiangsu, China) will be inserted in GV20（Baihui) and the stainless needle(size 0.25mm×25mm, described above) will be inserted in GV26 (Shuigou), acupoints will be stimulated manually until patients feel soreness, distension or heaviness (the reaction of De Qi). Then, the needles are stimulated by using an acupuncture point nerve stimulator (HANS-200, Nanjing Jinsheng, Ltd., China) with a frequency of 2/100 Hz and an intensity of 3 mA for 40 min (a homemade relay cycled power to the electrode for 6 sec on and 6 sec off), 28 days as a course of treatment, once a day.
Study: NCT06329661

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporine ophthalmic solution, 0.1%
Description: Colorless and clear opthalmic solution containing 0.1% Cyclosporine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline solution, 0.6%
Description: Colorless and clear sodium chloride solution (0.6%)
Study: NCT05130866

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REC-2282
Description: Participants will receive REC-2282 3 times per week orally for 3 weeks followed by 1 week off for a 4-week cycle.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo orally 3 times per week for 3 weeks followed by 1 week off for a 4-week cycle.
Study: NCT06221345

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Systane HYDRATION® Preservative-Free Lubricant Eye Drops
Description: The HPG/HA group will receive Systane HYDRATION® Preservative-Free Lubricant Eye Drops and standard of care, i.e., prednisolone acetate (Pred forte®) and levofloxacin (Cravit®), at the dosage of 1-2 drops 4 times daily for 3 weeks from Weeks 1 to 4 post-op

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Optive Fusion® Lubricant Eye Drops (Unit Dose)
Description: The CMC/HA group will receive Optive Fusion® Lubricant Eye Drops (Unit Dose) and standard of care, i.e., prednisolone acetate (Pred forte®) and levofloxacin (Cravit®), at the dosage of 1-2 drops 4 times daily for 3 weeks from Weeks 1 to 4 post-op
Study: NCT04918537

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Walnuts
Description: 30g of plain walnuts in addition to habitual food intakes
Study: NCT05527691

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SupportGroove
Description: An app-delivered program consisting of positive psychology-based activities, such as expressing gratitude, finding meaning, savoring, and fostering connections. Participants complete daily quests suggested through the app, some of which are completed on their own, and some with their partner.
Study: NCT06585176

Intervention type: OTHER
Intervention: No intervention
Description: This concerns a natural history study. No interventions will be used.
Study: NCT05733793

Intervention type: OTHER
Intervention: NGS tests
Description: This study is an observational, the patients with have an available NGS report performed in context of clinical practice or collected in clinical trials.~Patients enrolled in the current study will be managed as for clinical practice and no additional genetic tests or other procedure will be required.

Intervention type: OTHER
Intervention: NGS tests
Description: This study is an observational, the patients with have an available NGS report performed in context of clinical practice or collected in clinical trials.~Patients enrolled in the current study will be managed as for clinical practice and no additional genetic tests or other procedure will be required.
Study: NCT06061718

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: iDose TR
Description: anchored intracameral implant containing travoprost
Study: NCT06567093

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Baby Foot and Leg Massage
Description: Baby Foot Massage stages~* The baby is placed on his back, either on the bed or on the couch.~* One of the baby's feet is lifted into the air by grasping the back of the ankle.~* Start stroking with circular movements, starting from the heel and moving up to the toes. Stroking should be done with the thumb.~* Here, it might be good to get between the toes.~* The same procedure is applied to the other foot.~* Massage is continued until it is noticed that the baby calms down.~Baby Leg Massage stages~* Start by lifting the leg to be massaged.~* Here, the palms of both hands are used. The baby's leg is placed between both hands and the leg is stroked by moving the palms in opposite directions. This movement is continued from above the ankle to the hip.~* The same procedure is applied to the other leg.~* Massage is continued until the baby calms down.
Study: NCT06534970

Intervention type: DEVICE
Intervention: Three-dimensional stereophotogrammetry
Description: Three stereoscopic photographs

Intervention type: OTHER
Intervention: Questionnaires
Description: * SF-36 quality of life scale for general health inquiry~* Rosenberg Self-Esteem Scale~* Self-perception scale
Study: NCT05652751

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: sham EA
Description: The only difference between sham EA intervention and EA intervention is that the stimulator is connected to the needle handle without power for 40 min intervention.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: sham EA
Description: The only difference between sham EA intervention and EA intervention is that the stimulator is connected to the needle handle without power for 40 min intervention.
Study: NCT06385418

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colonic local administration of fluorouracil with enhanced adhesion
Description: Fluorouracil is administered via the colon as an injectable solution at a dose of 500 mg per day for 6 days, along with poloxamer 407 and poloxamer 188 used as thermosensitive hydrogel to enhance adhesion.
Study: NCT05888402

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Two cycles of induction Toripalimab (240mg every 3 weeks) plus platinum-based doublet chemotherapy as induction chemoimmunotherapy.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiation therapy and consolidation immunotherapy
Description: Thoracic radiation therapy (54-66Gy/25-33F/5-7week), concurrently with platinum-based doublet chemotherapy, followed by consolidation Toripalimab (240mg every 3 weeks) as consolidation immunotherapy for up to 12 months.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Concurrent chemoradiation therapy and consolidation immunotherapy
Description: Thoracic radiation therapy (54-66Gy/25-33F/5-7week), concurrently with platinum-based doublet chemotherapy, followed by consolidation Toripalimab (240mg every 3 weeks) as consolidation immunotherapy for up to 12 months.
Study: NCT05642663

Intervention type: DEVICE
Intervention: Stapler
Description: Stapling performed with ALTUS Powered Stapler
Study: NCT06087185

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful Eating
Description: Mindful Eating practices will be taught during a weekly meeting lasting 150 minutes and individuals will be encouraged to integrate the practices learned into their daily lives, for at least 15 minutes a day, being progressively integrated into the other practices that will be taught in subsequent weeks. There will be a WhatsApp group with reminders during the week and audio for guided practice.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Video Group
Description: Composed of 5 videos sent weekly produced by trained professionals. The topics discussed will be relevant to the management of anxiety in general and lifestyle changes.~Video 1: Psychoeducation of anxiety. Video 2: Healthy eating. Video 3: Sleep hygiene. Video 4: Physical activity. Video 5: Substance use. This protocol used as a control was effective as a Psychoeducation Group in improving anxiety symptoms in patients with generalized anxiety disorder.
Study: NCT04775368

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Administering diagnosis orientation questionnaires for the screening of possible sleep disorders
Description: Several diagnosis orientation self-questionnaires will be conducted by the patient following his or her inclusion in order to detect, among other things, possible sleep disorders.
Study: NCT05795517

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK31679 low dose
Description: HSK31679 low dose and placebo of HSK31679 ，QD，oral，Day1 to week 12

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK31679 medium dose
Description: HSK31679 medium dose and placebo of HSK31679 ，QD，oral，Day1 to week 12

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK31679 high dose
Description: HSK31679 high dose and placebo of HSK31679 ，QD，oral，Day1 to week 12

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo ，QD，oral，Day1 to week 12

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ezetimibe 10mg
Description: Ezetimibe 10mg+placebo of HSK31679 ，QD，oral，Day1 to week 12
Study: NCT04608474

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evolocumab
Description: Two different but equivalent drug dosing strategies are available. A 420mg monthly subcutaneous injection using an on-body infuser (Repatha Pushtronex system) or a 140mg subcutaneous injection once every two weeks using a prefilled auto-injector (Repatha SureClick). The choice of dosing strategy will be based on patient preference.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evolocumab
Description: Two different but equivalent drug dosing strategies are available. A 420mg monthly subcutaneous injection using an on-body infuser (Repatha Pushtronex system) or a 140mg subcutaneous injection once every two weeks using a prefilled auto-injector (Repatha SureClick). The choice of dosing strategy will be based on patient preference.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Statins (Cardiovascular Agents)
Description: Previously prescribed statin therapy.